Upon our population, four different management plans were considered, shockingly and although evidence-based medicine guidelines recommended TKIs as a first-line therapy for EGFR mutated NSCLC, they came second to chemotherapy in terms of the most commonly used treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.